Proteomics

Dataset Information

0

PSILAC mass spectrometry reveals ZFP91 as novel IMiD dependent substrate of the CRL4CRBN ligase - PART 2


ABSTRACT: Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of hematologic malignancies. It was shown that IMiDs impart gain of function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable binding, ubiquitination and degradation of key therapeutic targets such as IKFZ1, IKZF3 and CSNK1A1. While these substrates have been implicated as efficacy targets in multiple myeloma (MM) and 5q deletion associated myelodysplastic syndrome (del(5q)-MDS), other targets likely exist. Using a pulse-chase SILAC mass spectrometry-based proteomics approach, here we demonstrate that lenalidomide induces the ubiquitination and degradation of ZFP91. We establish that ZFP91 is a bona fide IMiD dependent CRL4CRBN substrate and further show that ZFP91 harbors a zinc finger (ZnF) motif, related to the IKZF1/3 ZnF, critical for IMiD dependent CRBN binding. These findings demonstrate that single time point pulse-chase SILAC mass spectrometry-based proteomics (pSILAC-MS) is a sensitive approach for target identification of small molecules inducing selective protein

OTHER RELATED OMICS DATASETS IN: PRJNA373859

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hek-293t Cell

SUBMITTER: Eric Fischer  

LAB HEAD: Eric Sebastian Fischer

PROVIDER: PXD005857 | Pride | 2017-05-29

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
140425_psilac_t6_1dmso_s01.raw Raw
140425_psilac_t6_1dmso_s02.raw Raw
140425_psilac_t6_1dmso_s03.raw Raw
140425_psilac_t6_1dmso_s04.raw Raw
140425_psilac_t6_1dmso_s05.raw Raw
Items per page:
1 - 5 of 208
altmetric image

Publications

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4<sup>CRBN</sup> ubiquitin ligase.

An Jian J   Ponthier Charles M CM   Sack Ragna R   Seebacher Jan J   Stadler Michael B MB   Donovan Katherine A KA   Fischer Eric S ES  

Nature communications 20170522


Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4<sup>CRBN</sup>) ubiquitin ligase that enable binding, ubiquitination and degradation of key therapeutic targets such as IKZF1, IKZF3 and CSNK1A1. While these substrates have been implicated as efficacy targets in multiple myeloma (MM) and 5q deletion associated myelodysplastic syndr  ...[more]

Similar Datasets

2017-03-01 | GSE94728 | GEO
2017-05-29 | PXD005849 | Pride
2011-09-30 | E-GEOD-31421 | biostudies-arrayexpress
2011-09-30 | E-GEOD-31451 | biostudies-arrayexpress
2014-05-13 | E-GEOD-57554 | biostudies-arrayexpress
2016-03-09 | E-GEOD-61693 | biostudies-arrayexpress
2011-10-01 | GSE31451 | GEO
2011-10-01 | GSE31421 | GEO
2016-03-09 | GSE61693 | GEO
2014-05-13 | GSE57554 | GEO